Hoth Therapeutics, Inc. (HOTH)
Company Description
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.
The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device.
The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003.
Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Country | United States |
Founded | 2017 |
IPO Date | Feb 15, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 2 |
CEO | Robb Knie |
Contact Details
Address: 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 United States | |
Phone | 551-578-2261 |
Website | hoththerapeutics.com |
Stock Details
Ticker Symbol | HOTH |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.60 |
CIK Code | 0001711786 |
CUSIP Number | 44148G105 |
ISIN Number | US44148G2049 |
Employer ID | 82-1553794 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Robb Knie | President, Chief Executive Officer and Chairman |
David S. Briones | Chief Financial Officer |
Hayley Springer | Executive Vice President of Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | 10-K | Annual Report |
Mar 28, 2024 | 424B3 | Prospectus |
Mar 28, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 9, 2024 | 8-K | Current Report |
Nov 13, 2023 | 10-Q | Quarterly Report |
Oct 5, 2023 | 8-K | Current Report |
Sep 15, 2023 | 8-K | Current Report |
Sep 14, 2023 | 424B5 | Filing |
Aug 21, 2023 | 8-K | Current Report |